Application of Xihuang pills in nodules

Xihuang Wan solves the treatment problems of breast nodules and thyroid nodules through oral administration. By inhibiting the release of inflammatory factors, it reduces breast hyperplasia and thyroid imbalance, and achieves the protection and treatment effect on the breast and thyroid glands.

CN118948924APending Publication Date: 2024-11-15LONGHUI PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310540368.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-15
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat breast nodules and thyroid nodules, and there is a lack of effective drug treatment options.

Method used

Xihuang Wan is a drug that is orally administered to treat breast nodules and thyroid nodules. It has the effect of preventing and treating breast hyperplasia, inhibiting breast tumor growth, and regulating the balance of thyroid function. It may inhibit the release of inflammatory factors in the serum. To achieve these effects.

Benefits of technology

Xihuang Pills can reduce the degree of breast hyperplasia, relieve the pathological damage of breast tissue, inhibit the expression of angiogenic factors, and protect the breast. It also reduces the thyroid index and regulates thyroid function in thyroid nodule model rats, and provides clinical treatment guidance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948924A_ABST
    Figure CN118948924A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicine application, and particularly relates to application of Xihuang pills in nodules. The medicine can be applied as a medicine for treating breast nodules and thyroid nodules. The traditional Chinese medicine composition can be applied to preparation of medicines for treating breast nodules and thyroid nodules. The compound can be applied as a medicine for treating mouse breast nodules and thyroid nodules. The effect of preventing and treating breast cancer is achieved by inhibiting release of inflammatory factors in serum. The Western Huang pill can reduce the thyroid index of a thyroid nodule model rat caused by propylthiouracil, relieve tissue pathological damage and have the effect of adjusting thyroid function balance. And an instructive effect is achieved for clinical treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug application, and particularly relates to the application of Xihuang Pills in nodules. Background Art

[0002] Breast nodules and thyroid nodules are two common nodule-prone diseases. Breast nodules are structural degenerative lesions of breast tissue ducts and lobules and progressive connective tissue growth, and the main cause of the disease is endocrine hormone imbalance. Thyroid nodules refer to one or more lumps with abnormal tissue structure in the thyroid gland due to various reasons such as radiation exposure. Thyroid nodules are extremely common in clinical practice, and are common in women. The clinical manifestations are lumps in the neck, stuffiness in the neck and shortness of breath. There is a feeling of plugging in the pharynx, or accompanied by palpitations, irritability, irritability, and sweating; a few people may have neck pain and hoarseness. More research has been done on the two diseases for many years, and there are more therapeutic drugs to treat them. This case was formed after years of research. Summary of the invention

[0003] In order to solve the above problems, that is, to solve the problems raised by the above background technology, the present invention proposes the application of Xihuang Pills in nodules, and the specific technical scheme is as follows:

[0004] The application of Xihuang Pills in nodules, as a drug for the treatment of breast nodules and thyroid nodules.

[0005] As an application in the preparation of medicines for treating breast nodules and thyroid nodules.

[0006] Application as a drug for treating mouse breast nodules and thyroid nodules.

[0007] The beneficial technical effects of the present invention are as follows: through the research of the present invention, it is proved that Xihuang Pills have the effects of preventing and treating breast hyperplasia, inhibiting breast tumor growth, regulating thyroid function balance, etc., which are specifically manifested in that Xihuang Pills can reduce the degree of breast hyperplasia, relieve breast tissue pathological damage, regulate the balance of reproductive hormones, inhibit the expression of angiogenic factors, and protect the breast. Xihuang Pills have an anti-tumor effect on 4T1 breast cancer tumor-bearing mice, and its mechanism may be achieved by inhibiting the release of inflammatory factors in serum to prevent and treat breast cancer. Xihuang Pills can reduce the thyroid index of rats with thyroid nodules caused by propylthiouracil, alleviate tissue pathological damage, and have the effect of regulating the balance of thyroid function. It plays a guiding role in clinical treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] Figure 1 This is the HE staining picture of breast tissue of the present invention;

[0009] Figure 2 This is the VEGF immunohistochemistry diagram of the present invention;

[0010] Figure 3 This is the immunohistochemistry diagram of BFGF of the present invention;

[0011] Figure 4 This is the HE staining picture of the thyroid gland of the present invention. DETAILED DESCRIPTION

[0012] The preferred embodiments of the present invention are described below. It should be understood by those skilled in the art that these embodiments are only used to explain the technical principles of the present invention and are not intended to limit the protection scope of the present invention.

[0013] Embodiment 1

[0014] Effect of Xihuang Pills on Rat Model of Mammary Hyperplasia

[0015] 1. Experimental Materials

[0016] 1.1 Experimental animals

[0017] 60 SPF-grade SD rats, female, weighing 200-220 g, were purchased from the Experimental Animal Center of Heilongjiang University of Chinese Medicine, with animal production license number: SCXK (Heilongjiang) 2018-003. The animals were housed in a clean laboratory (temperature 20-26°C, relative humidity 40%-70%) for 5 days and were allowed to drink water and eat freely.

[0018] 1.2 Experimental drugs

[0019] 1.2.1 Clinical dosage and source of test article

[0020] Name: Xihuang Pills Clinical usage and dosage: Oral, 3g / time, 2 times / day.

[0021] Source: Longhui Pharmaceutical Co., Ltd.

[0022] Production batch number: 20180903

[0023] 1.2.2 Clinical dosage and source of positive control drugs

[0024] Name: Pingxiao Capsules

[0025] Clinical usage and dosage: Oral administration, 0.23g / pill, 4-8 pills / time, 3 times / day.

[0026] Source: Xi'an Zhengda Pharmaceutical Co., Ltd.

[0027] Product batch number: 210425

[0028] 1.3 Experimental instruments and reagents

[0029] Estradiol Benzoate Injection Shanghai Quanyu Biotechnology Animal Pharmaceutical Co., Ltd.

[0030] Progesterone Injection Shanghai Quanyu Biotechnology Animal Pharmaceutical Co., Ltd.

[0031] Estradiol (E2) ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0032] Progesterone (P) ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0033] Prolactin (PRL) ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0034] YP10001 Electronic Balance Shanghai Youke Instrument Co., Ltd.

[0035] JA5003 Analytical Balance Shanghai Liangping Instrument Co., Ltd. 150 High Carbon Steel Vernier Caliper Su Ce Nscing

[0036] Histopathology dehydrator Leica Germany

[0037] Histopathology embedding machine Leica Germany

[0038] Histopathology slicer Leica Germany

[0039] Tissue section staining machine German Leica

[0040] Histopathology sealing machine Leica Germany

[0041] BioTek fully automatic microplate reader

[0042] 2. Experimental Procedure

[0043] 2.1 Animal model preparation

[0044] Sixty SPF-grade SD female healthy non-pregnant rats were randomly divided into a blank control group of 10 and an experimental group of 50. The experimental group used intramuscular injection of estradiol benzoate and progesterone to replicate the female rat breast hyperplasia model. Estradiol benzoate injection was injected intramuscularly on the outside of the rat's hind limbs, with a dose standard of 0.5 mg / kg·d according to body weight, once a day, alternating between the left and right limbs, for 20 consecutive days; on the 21st day, it was replaced with progesterone injection, and continued intramuscular injection, with a dose standard of 5 mg / kg·d according to body weight, once a day, for 5 consecutive days.

[0045] 2.2 Experimental Animal Grouping and Dosing

[0046] The 50 rats with successful modeling were randomly divided into 5 groups, namely the model group, Xihuang Pill low-dose group, medium-dose group, high-dose group and positive control group (Pingxiao Capsule), with 10 rats in each group.

[0047] Low-dose group: 0.54 g / kg·d, once a day, for 28 consecutive days Medium-dose group: 1.08 g / kg·d, once a day, for 28 consecutive days

[0048] High-dose group: 2.16 g / kg / d by gavage, once a day, for 28 consecutive days

[0049] Positive control group: Oral administration of 0.37 g / kg / day once a day for 28 consecutive days. Model group rats were given an equal volume (1 ml / 100 g body weight) of normal saline once a day for 28 consecutive days. 2.3 Index detection

[0050] 2.3.1 Effect of Xihuang Pills on the General State, Body Weight, and Breast Diameter of Rats with Mammary Hyperplasia Model The spirit and activity state of the rats, as well as changes in external manifestations such as breast shape and size, were observed daily. The body weight of the rats was measured before administration and at the second and fourth weekends after administration. The diameter of the second pair of nipples of the rats in each group was measured with a vernier caliper before and after administration.

[0051] 2.3.2 Effect of Xihuang Pills on Breast Tissue Pathological Morphology

[0052] The rats were killed, and the second pair of bilateral nipples and mammary gland tissues were removed for routine HE staining. The cross-sectional area of ​​mammary gland tissue was measured, and the number of mammary gland lobules, the number of alveoli in mammary gland lobules (pieces / lobe) and the diameter of alveolar cavity (μm) were calculated. The pathological morphological changes of mammary gland tissue structure were observed under a light microscope.

[0053] 2.3.3 Regulatory effect of Xihuang Pills on related hormone levels in serum of rats with mammary hyperplasia model On the day after the last administration, the rats were anesthetized with 3% sodium pentobarbital, blood was collected from the abdominal aorta to separate serum, and ELISA was used to detect the levels of estradiol (E2), progesterone (P), and prolactin (PRL) in the serum.

[0054] 2.3.4 Effect of Xihuang Pills on the Expression of Related Proteins in Rats with Breast Hyperplasia Immunohistochemistry was used to detect the expression of fibroblast growth factor (BFGF) and vascular endothelial growth factor (VEGF) in mammary tissue. BFGF and VEGF were positive when brown-yellow granules appeared in the cytoplasm. Five areas were randomly selected under a 200x microscope, and the average optical density value was determined using an image analysis system.

[0055] 3. Statistical Analysis

[0056] The comparison between experimental data groups was performed with t-test using social science statistical program software SPSS17.0, and the results were expressed as x±S.

[0057] 4. Experimental Results

[0058] 4.1 Effect of Xihuang Pills on the General State, Weight, and Breast Diameter of Rats with Hyperplasia of Mammary Gland During the modeling period, the blank control group rats had smooth fur, free movement, good appetite, and normal urination and defecation. The rats in each modeling group were more sensitive, irritable, and aggressive; after the modeling, the nipples of the blank control group rats were not easy to see. After the hair was separated, the nipples were millet-like, similar to the surrounding skin, soft, flat, and close to the skin, with some slightly raised; the nipples of the rats in the other groups were erected on the skin surface compared with the blank control group, and were firm, congested, and swollen.

[0059] Table 1 Effect of Xihuang Pills on body weight of rats with mammary hyperplasia model

[0060]

[0061] Note: Compared with the blank control group, ΔΔ P<0.01.

[0062] The results in Table 1 show that before administration, the body weight of each group was significantly reduced compared with the blank control group, and the difference was statistically significant (P < 0.01), indicating that the development of the disease had a significant impact on the growth of the animals.

[0063] Compared with the blank control group, the body weight of the model group decreased significantly at the 2nd and 4th weeks of administration, and the difference was statistically significant (P < 0.01). Compared with the model group, the body weight of the Xihuang Pills administration groups showed an increasing trend after treatment, but the difference was not statistically significant (P > 0.05).

[0064] Table 2 Effect of Xihuang Pills on nipple diameter in rats with mammary hyperplasia model

[0065]

[0066] Note: Compared with the blank control group, ΔΔ <0.05; compared with the model group, *P<0.05, **P<0.01.

[0067] The results in Table 2 show that before drug administration, the nipple diameter of each group increased significantly compared with the blank control group, and the difference was significant (P < 0.01), indicating that the model was successfully established.

[0068] Compared with the two groups, the diameter of the nipple increased significantly, and the difference was significant (P < 0.01); the medium dose of Xihuang Pill

[0069] Compared with the model group, the nipple diameter of the positive control group and the model group was significantly reduced, and the difference was statistically significant (P<0.05, P<0.01).

[0070] 4.2 Effect of Xihuang Pills on the pathological morphology of mammary hyperplasia model rats

[0071] Blank control group: The mammary glands and ducts of the rats were clearly visible without dilatation, without proliferative pathological changes, with a small number of mammary lobules and narrow mammary alveolar cavities.

[0072] Model group: The number of mammary lobules and alveoli in the mammary glands of rats increased significantly, epithelial proliferation was active, glands and ducts expanded significantly, and a large amount of secretions appeared.

[0073] Treatment group: The degree of mammary gland hyperplasia in rats in the medium and high dose groups was alleviated, ductal hyperplasia and dilatation were significantly improved, and the number and diameter of mammary gland lobules and alveoli were significantly reduced. Figure 1 .

[0074] Table 3 Effects of Xihuang Pills on mammary lobules and alveoli in rats with breast hyperplasia model

[0075]

[0076] Note: Compared with the blank control group, ΔΔ <0.05; compared with the model group, *P<0.05, **P<0.01.

[0077] The results in Table 3 show that compared with the blank control group, the number of mammary lobules, the number of alveoli and the diameter of the alveolar cavity in the model group were significantly increased, and the difference was significant (P < 0.01); after drug treatment, compared with the model group, the number of mammary lobules, the number of alveoli and the diameter of the alveolar cavity in the medium and high dose groups of Xihuang Pills and the positive control group were significantly reduced, and the diameter of the mammary alveolar cavity in the low dose group was also significantly reduced, and the difference was significant (P < 0.05, P < 0.01).

[0078] 4.3 Regulatory effect of Xihuang Pills on serum related hormone levels in rats with mammary hyperplasia model

[0079] Table 4 Effects of Xihuang Pills on serum hormones in rats with mammary hyperplasia model

[0080]

[0081] Note: Compared with the blank control group, △△ P<0.01; compared with the model group, *P<0.05, **P<0.01.

[0082] The results in Table 4 show that compared with the blank control group, the model group had significantly increased estradiol (E2) and prolactin (PRL) in the rat serum, and significantly decreased progesterone (P), with significant differences (P < 0.01); after drug treatment, compared with the model group, the estradiol (E2) and prolactin (PRL) in the rat serum of each dose group of Xihuang Pills and the positive control group were decreased, with significant differences (P < 0.05, P < 0.01). Compared with the model group, the progesterone (P) in the rat serum of the medium and high dose groups of Xihuang Pills was increased, with significant differences (P < 0.05).

[0083] 4.4 Effect of Xihuang Pills on the Expression of Related Proteins in Rats with Breast Hyperplasia Model

[0084] BFGF and VEGF protein positive staining was mainly localized in the cytoplasm, with strong positive expression in the model group and weak positive expression in the low, medium, high dose groups and positive control group. Figure 2 , 3 .

[0085] Table 5 Effect of Xihuang Pills on the expression of related proteins in rats with mammary hyperplasia model

[0086]

[0087] Note: Compared with the model group, *P<0.05, **P<0.01.

[0088] The results in Table 5 showed that compared with the model group, the expressions of VEGF and BFGF in breast tissue of the low-, medium-, and high-dose groups of Xihuang Pills and the positive control group were decreased, and the differences were statistically significant (P < 0.05, P < 0.01).

[0089] Embodiment 2

[0090] Effect of Xihuang Pills on Breast Cancer Model Mice

[0091] 1. Experimental Materials

[0092] 1.1 Experimental animals

[0093] Female Balb / c mice, weighing 18-20 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. The animals were housed in an SPF-grade laboratory (temperature 20-26° C., relative humidity 40%-70%) for 2 days with free access to water and food.

[0094] 1.2 Experimental drugs

[0095] 1.2.1 Clinical dosage and source of test article

[0096] Name: Xihuang Pills

[0097] Clinical usage and dosage: Oral, 3g / time, 2 times / day.

[0098] Source: Longhui Pharmaceutical Co., Ltd.

[0099] Production batch number: 20180903

[0100] 1.2.2 Clinical dosage and source of positive control drugs

[0101] Name: Compound cyclophosphamide tablets Clinical usage and dosage: Oral, 1 tablet / time, 3-4 times / day.

[0102] Source: Tonghua Maoxiang Pharmaceutical Co., Ltd.

[0103] Product batch number: 20210325

[0104] 1.3 Experimental instruments and reagents

[0105] Breast cancer 4T1 cell line was provided by Heilongjiang Provincial Cancer Hospital.

[0106] Hanks Liquid Shanghai Yiji Industrial Co., Ltd. (Batch No.: 2020.10.21)

[0107] Calf serum Shanghai Yiji Industrial Co., Ltd. (Batch number: 2021022511)

[0108] Penicillin-Streptomycin Mixture (100X) Biotopped (Batch No.: 200913)

[0109] PBS Biotopped (Batch No.: 201103)

[0110] Trypsin Cell Digestion Solution Beyotime RPMI 1640 Medium HyClone IL-2 ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0111] IL-6 ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0112] Interferon-γ ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0113] TNF-α ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0114] YP10001 Electronic Balance Shanghai Youke Instrument Co., Ltd.

[0115] JA5003 Analytical Balance Shanghai Liangping Instrument Co., Ltd.

[0116] Histopathology dehydrator Leica Germany

[0117] Histopathology embedding machine Leica Germany

[0118] Histopathology slicer Leica Germany

[0119] Tissue section staining machine German Leica

[0120] Histopathology sealing machine Leica Germany

[0121] 2. Experimental Procedure

[0122] 2.14T1 cell recovery

[0123] (1) Prepare a beaker filled with 37°C warm water, take out the cryotube containing 4T1 cells from the liquid nitrogen tank, place it in 37°C warm water, hold it with tweezers and gently shake it to melt it quickly. Centrifuge at 2000r for 4min. (2) Use 75% ethanol to thoroughly wipe the cryotube on a sterile operating table, then open the cryotube, being careful to be gentle.

[0124] (3) Remove the supernatant with a 1 ml pipette tip, add 1 ml of preheated cell culture medium to disperse the cells, and transfer them to a 25 cm2 culture flask.

[0125] (4) Supplement with 4 ml of RPMI 1640 medium (containing 10% fetal bovine serum).

[0126] (5) Observe under an inverted microscope and culture at 37°C and 5% CO2. After 24 hours, replace the culture medium with new one and perform routine subculture.

[0127] 2.24T1 cell passaging

[0128] ① Open the cap of the culture bottle under sterile operation and pour out the culture medium.

[0129] ② Add 1 ml of digestion solution to the overgrown cells, gently shake the culture bottle to allow the digestion solution to flow over all cell surfaces, aspirate or pour it out, and gently rinse the cell surface 2 to 3 times to remove as much bovine serum as possible in the original culture medium.

[0130] ③ Add 1 ml of digestion solution, incubate in a 37°C incubator for 5 to 8 minutes, then place the culture flask under an inverted microscope for observation. When the cell cytoplasm shrinks and the intercellular matrix enlarges, terminate the digestion immediately.

[0131] ④ Add 5 ml of culture medium preheated to 37°C and repeatedly blow with a glass pipette to disperse the cells. The blowing process should be carried out in sequence, starting from one side of the bottom of the culture bottle and ending at the other side to ensure that all the bottoms are blown.

[0132] ⑤ Take half of the cell suspension and inoculate it into a new 25cm2 culture bottle, and add culture medium (containing 10% to 20% fetal bovine serum). Usually the amount of liquid in each bottle is 5 to 10 ml.

[0133] ⑥Observe under an inverted microscope and culture at 37℃ and 5% CO2.

[0134] 2.3 Animal model establishment

[0135] 4T1 cells with good growth index were taken and inoculated into the right axillary subcutaneous tissue of 50 female Balb / c mice with 0.2 ml each (density of 1×107 / L). Tumors grew after about 1 week. Drug treatment was started when the tumor diameter reached 3-5 mm.

[0136] 2.4 Grouping and Dosage Method

[0137] The mice with successful modeling were randomly divided into 5 groups, namely, model group, Xihuang Pill low-dose group, medium-dose group, high-dose group and positive control group, with 10 mice in each group.

[0138] Low-dose group: 0.78 g / kg·d, once a day, for 14 consecutive days Medium-dose group: 1.56 g / kg·d, once a day, for 14 consecutive days

[0139] High-dose group: 3.12 g / kg·d, once a day, for 14 consecutive days Positive control group: 20 mg / kg·d, once a day, for 14 consecutive days Model group mice were given an equal volume (0.4 ml / 20 g body weight) of normal saline, once a day, for 14 consecutive days 2.5 index detection

[0140] 2.5.1 Effect of Xihuang Pills on Tumor Inhibition in 4T1 Breast Cancer Model Mice

[0141] The next day after drug withdrawal, the tumor-bearing mice were weighed, the mice were killed, the tumor masses were weighed, and the tumor inhibition rate was calculated.

[0142] Tumor growth inhibition rate (%) = (average tumor weight of control group - average tumor weight of treatment group) / average tumor weight of control group * 100%.

[0143] 2.5.2 Effect of Xihuang Pills on the Immune Function of 4T1 Breast Cancer Model Mice

[0144] The mice were weighed and then killed. The mice were soaked in 75% alcohol for half an hour, and then the spleen was aseptically removed and weighed using an electronic balance. The spleen index and thymus index were calculated according to the following formula.

[0145] Spleen index (mg / g) = spleen mass (mg) / body weight (g) * 100%

[0146] Thymus index (mg / g) = thymus mass (mg) / body weight (g) * 100%

[0147] 2.5.3 The regulatory effect of Xihuang Pills on cytokines in 4T1 breast cancer model mice The eyeballs of mice were removed to collect blood, and the serum was separated. The ELISA method was used to detect interleukin-2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor (TNF-α), and gamma-interferon in the serum of rats in each group to observe the regulatory effect of Xihuang Pills on cytokine levels.

[0148] 3. Statistical Analysis

[0149] The comparison between experimental data groups was performed with t-test using social science statistical program software SPSS17.0, and the results were expressed as x±S.

[0150] 4. Experimental Results

[0151] 4.1 Effect of Xihuang Pills on Tumor Inhibition in 4T1 Breast Cancer Model Mice

[0152] Table 6 In vivo tumor inhibition effect of Xihuang Pills on 4T1 tumor-bearing mice

[0153]

[0154] Note: Compared with the model group, *P<0.05, **P<0.01.

[0155] The results in Table 6 show that each dose group of Xihuang Pills had different degrees of inhibitory effect on 4T1 solid tumors. The tumor weight was significantly different from that of the model group (P < 0.05, P < 0.01). The tumor inhibition rates of the low, medium and high dose groups were 17.38%, 36.80% and 22.51%, respectively, indicating that Xihuang Pills had an inhibitory effect on 4T1 tumor-bearing mice.

[0156] 4.2 Effect of Xihuang Pills on the Immune Function of 4T1 Breast Cancer Model Mice

[0157] Table 7 Effects of Xihuang Pills on immune organs of 4T1 breast cancer model mice

[0158]

[0159] Note: Compared with the model group, *P<0.05, **P<0.01.

[0160] The results in Table 7 show that there was no significant difference in body weight between the Xihuang Pills in each dose group and the model group before the experiment (P>0.05); after 14 days of drug treatment, the body weight of the Xihuang Pills medium and high dose groups and the cyclophosphamide group was significantly reduced compared with the model group (P<0.01); the thymus index of the Xihuang Pills medium and high dose groups was significantly increased compared with the model group (P<0.01). The spleen index of the Xihuang Pills low, medium and high dose groups was significantly increased compared with the model group (P<0.05, P<0.01).

[0161] 4.3 Regulatory effect of Xihuang Pills on cytokines in 4T1 breast cancer model mice

[0162] Table 8 Regulatory effect of Xihuang Pills on cytokine levels in 4T1 breast cancer model mice

[0163]

[0164] Note: Compared with the model group, *P<0.05, **P<0.01.

[0165] The results in Table 8 showed that compared with the model group, the levels of IL-2, TNF-α, and IFN-γ in peripheral blood of the medium-dose and high-dose Xihuang Pills groups and the cyclophosphamide group were increased, and the differences were significant (P < 0.05, P < 0.01); compared with the model group, the level of IL-6 in peripheral blood of the high-dose Xihuang Pills group and the cyclophosphamide group was decreased, and the differences were significant (P < 0.05).

[0166] Embodiment 3

[0167] Effect of Xihuang Pills on Thyroid Nodule Model Rats

[0168] 1. Experimental Materials

[0169] 1.1 Experimental animals

[0170] 60 SPF SD rats, weighing 200-220 g, female, were purchased from the Experimental Animal Center of Heilongjiang University of Chinese Medicine, with animal production license number: SCXK (Heilongjiang) 2018-003. The animals were housed in a clean laboratory (temperature 20-26°C, relative humidity 40%-70%) for 5 days, with free access to water and food.

[0171] 1.2 Experimental drugs

[0172] 1.2.1 Clinical dosage and source of test article

[0173] Name: Xihuang Pills

[0174] Clinical usage and dosage: Oral, 3g / time, 2 times / day.

[0175] Source: Longhui Pharmaceutical Co., Ltd.

[0176] Production batch number: 20180903

[0177] 1.2.2 Clinical dosage and source of positive control drugs

[0178] Name: Levothyroxine Sodium Tablets

[0179] Clinical usage and dosage: Oral, 50-200μg / day.

[0180] Source: Merck Pharmaceuticals (Jiangsu) Co., Ltd.

[0181] Product batch number: 010005923

[0182] 1.3 Experimental instruments and reagents

[0183] Propylthiouracil Shanghai Quanyu Biotechnology Animal Pharmaceutical Co., Ltd.

[0184] TT3 ELISA Kit Shanghai Quanyu Biotechnology Animal Pharmaceutical Co., Ltd.

[0185] TT4 ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0186] FT3 ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0187] FT4 ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0188] TSH ELISA Kit Nanjing Jiancheng Biological Co., Ltd.

[0189] YP10001 Electronic Balance Shanghai Youke Instrument Co., Ltd.

[0190] JA5003 Analytical Balance Shanghai Liangping Instrument Co., Ltd.

[0191] Histopathology dehydrator Leica Germany

[0192] Histopathology embedding machine Leica Germany

[0193] Histopathology slicer Leica Germany

[0194] Tissue section staining machine German Leica

[0195] Histopathology sealing machine Leica Germany

[0196] BioTek fully automatic microplate reader

[0197] 2. Experimental Procedure

[0198] 2.1 Animal model preparation

[0199] 60 SPF SD female rats were adaptively fed for 5 days. Ten rats were randomly selected as the blank control group, and the rest of the rats were gavaged with propylthiouracil to prepare the nodular goiter model. The rats were gavaged once a day at a dose of 0.01 g / (kg·d), and each group was gavaged for 21 consecutive days.

[0200] 2.2 Grouping and dosing method

[0201] The 50 rats with successful modeling were randomly divided into 5 groups, namely, model group, Xihuang Pill low-dose group, medium-dose group, high-dose group and positive control group, with 10 rats in each group.

[0202] Low-dose group: 0.54 g / kg·d, once a day, for 28 consecutive days Medium-dose group: 1.08 g / kg·d, once a day, for 28 consecutive days

[0203] High-dose group: Oral administration of 2.16 g / kg·d, once a day, for 28 consecutive days Positive control group: Oral administration of 0.01 mg / kg·d, once a day, for 28 consecutive days Model group rats were given an equal volume (1 ml / 100 g body weight) of normal saline, once a day, for 28 consecutive days 2.5 index detection

[0204] 2.5.1 Effect of Xihuang Pills on Thyroid Weight and Index of Thyroid Nodule Model Rats On the day after the last administration, the rats were weighed and killed under 3% pentobarbital anesthesia. The thyroid gland of each rat was removed, rinsed with cold saline, dried with filter paper, weighed, and the thyroid index was calculated according to the following formula.

[0205] Thyroid index (mg / g) = thyroid mass (mg) / body weight (g) * 100%

[0206] 2.5.2 Effect of Xihuang Pills on the Pathological Morphology of Thyroid Nodule Model Rats

[0207] Hematoxylin-eosin (HE) staining was performed and the pathological morphological changes of the rat thyroid gland were observed under a light microscope.

[0208] 2.5.3 Regulatory effect of Xihuang Pills on thyroid function in rats with thyroid nodule model. On the day after the last administration, the rats were anesthetized with 3% sodium pentobarbital, and blood was collected from the abdominal aorta to separate serum. ELISA was used to detect the levels of total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine (FT3), free thyroxine (FT4) and thyroid stimulating hormone (TSH) in the serum of rats in each group to observe the regulatory effect of Xihuang Pills on thyroid function.

[0209] 3. Statistical Analysis

[0210] The comparison between experimental data groups was performed with t-test using social science statistical program software SPSS17.0, and the results were expressed as x±S.

[0211] 4. Experimental Results

[0212] 4.1 Effects of Xihuang Pills on Thyroid Weight and Index in Thyroid Nodule Model Rats

[0213] Table 9 Effects of Xihuang Pills on thyroid weight and index of rats in each group

[0214]

[0215] Note: Compared with the blank control group, ΔΔ <0.01; compared with the model group, *P<0.05, **P<0.01.

[0216] The results in Table 9 show that compared with the blank control group, the model group had a significantly decreased body weight, and a significantly increased thyroid weight and index, and the differences were statistically significant (P < 0.01); after drug treatment, compared with the model group, the body weight of the medium- and high-dose groups of Xihuang Pills and the positive control group was increased, and the difference was statistically significant (P < 0.05); compared with the model group, the thyroid weight of the high-dose group of Xihuang Pills and the positive control group was decreased, and the difference was statistically significant (P < 0.05, P < 0.01); compared with the model group, the thyroid index of the medium- and high-dose groups of Xihuang Pills and the positive control group was decreased, and the difference was statistically significant (P < 0.05, P < 0.01).

[0217] 4.2 Effect of Xihuang Pills on the pathological morphology of thyroid nodule model rats

[0218] Blank group: The thyroid tissue structure was clear, the follicular epithelial cells were low cubic or cubic, the follicular cavity was round or oval, the follicles were uniform in size, and the colloid content was rich.

[0219] Model group: The thyroid tissue structure was unclear, the number of thyroid cell nuclei increased, and they were tall columnar, with local stratification, reduced follicular cavity area, uneven size, and reduced colloid content.

[0220] Treatment group: The thyroid tissue structure of the medium and high dose groups of Xihuang Pills was relatively clear, the number of thyroid cell nuclei decreased, and they were arranged in a single layer. The follicular cavity area increased, the size was relatively consistent, and the colloid content increased; the thyroid tissue structure of the low dose group of Xihuang Pills was not clear, the number of thyroid cell nuclei decreased relatively, and they were arranged in a single layer, with few local stratifications. The follicular cavity area increased, but not as good as the medium and high dose groups, and the follicular size and colloid content were also low; the thyroid tissue structure of the positive control group was not clear, but better than the low dose group, the follicular cavity area increased, and the follicular size and colloid content were not as good as the medium and high dose groups. The results are attached. Figure 4.

[0221] 4.3 Regulatory effect of Xihuang Pills on thyroid function in rats with thyroid nodules

[0222] Table 10 Regulatory effect of Xihuang Pills on thyroid function in rats with thyroid nodules

[0223]

[0224] Note: Compared with the blank control group, ΔΔ <0.01; compared with the model group, *P<0.05, **P<0.01. .

[0225] The results in Table 10 show that compared with the blank control group, the model group had significantly increased TT3, TT4, FT3, and FT4 in the rat serum, and significantly decreased TSH, with significant differences (P < 0.01); after treatment, compared with the model control group, the serum FT4 of the rats in the medium-dose group of Xihuang Pills decreased, and TSH increased, while the serum TT3, TT4, and FT4 of the rats in the high-dose group and the positive control group decreased, and TSH increased, with significant differences (P < 0.05, P < 0.01). This shows that Xihuang Pills has the effect of regulating the balance of thyroid function.

[0226] By evaluating the pharmacodynamic effects of Xihuang Pills in treating breast nodules and thyroid nodules, an experimental basis is provided for clinical medication.

[0227] The term "comprise" or any other similar term is intended to cover a non-exclusive inclusion, such that a process, article, or apparatus / device that includes a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, article, or apparatus / device.

[0228] So far, the preferred embodiments describe the technical solutions of the present invention, but it is easy for those skilled in the art to understand that the protection scope of the present invention is obviously not limited to these specific embodiments. Without departing from the principle of the present invention, those skilled in the art can make equivalent changes or substitutions to the relevant technical features, and the technical solutions after these changes or substitutions will fall within the protection scope of the present invention.

Claims

1. The application of Xihuang Pills in treating nodules is characterized by: Use as a drug for the treatment of breast nodules and thyroid nodules.

2. The application of Xihuang Pills in treating nodules is characterized by: As an application in the preparation of medicines for treating breast nodules and thyroid nodules.

3. The application of Xihuang Pills in treating nodules is characterized by: Application as a drug for treating mouse breast nodules and thyroid nodules.

Citation Information

Patent Citations

  • Application of Chinese northwestern calculus bovis pellets in preparation of taxol drug-tolerant drug for treating breast cancer

    CN108785356A

  • Traditional Chinese medicine supersonic air jet crushing method

    CN110404654A